
Ernexa Therapeutics
(NASDAQ) ERNA
Ernexa Therapeutics Financials at a Glance
Market Cap
$7.11M
Revenue (TTM)
$0.00
Net Income (TTM)
-$11.39M
EPS (TTM)
-$30.72
P/E Ratio
-0.20
Dividend
$0.00
Beta (Volatility)
1.13 (Average)
Dividend
$0.00
Beta (Volatility)
1.13 (Average)
Price
$6.00
Volume
349,653.189
Open
$6.39
Price
$6.00
Volume
349,653.189
Open
$6.39
Previous Close
$6.10
Daily Range
$5.72 - $6.77
52-Week Range
$3.18 - $71.50
Estimated Earnings Date
Aug 17, 2026
Dividend
$0.00
Beta (Volatility)
1.13 (Average)
Price
$6.00
Volume
349,653.189
Open
$6.39
Previous Close
$6.10
Daily Range
$5.72 - $6.77
52-Week Range
$3.18 - $71.50
Estimated Earnings Date
Aug 17, 2026
ERNA News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Ernexa Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
5
CEO
Sanjeev Luther, MBA
Website
www.ernexatx.comHeadquarters
Cambridge, MA 92121, US
ERNA Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-2505%
Return on Capital
-1%
Return on Assets
-1%
Earnings Yield
-5.00%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$7.11M
Shares Outstanding
1.17M
Volume
349.65K
Avg. Volume
1.59M
Financials (TTM)
Gross Profit
$0.00
Operating Income
-$9.32M
EBITDA
-$13.84M
Operating Cash Flow
-$7.02M
Capital Expenditure
-$37.00K
Free Cash Flow
-$7.05M
Cash & ST Invst.
$1.88M
Total Debt
$490.00K
Ernexa Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
-$86.00K
N/A
Gross Margin
0.00%
N/A
Market Cap
$7.11M
N/A
Market Cap/Employee
$1.19M
N/A
Employees
6
N/A
Net Income
-$5.51M
+32.9%
EBITDA
-$5.46M
+32.8%
Quarterly Fundamentals
Total Cash
$9.18M
+378.5%
Total Debt
$389.00K
-86.5%
Accounts Receivable
$95.00K
-39.1%
Inventory
$0.00
N/A
Long Term Debt
$226.00K
-46.1%
Short Term Debt
$163.00K
-93.4%
Return on Assets
-1.08%
N/A
Return on Invested Capital
-1.43%
N/A
Free Cash Flow
-$2.27M
-9.7%
Operating Cash Flow
-$2.26M
-9.6%


